Shots:
- Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs
- As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan for the 2 programs, while Pierre will gain rest-of-world rights as well as exclusive global rights for a 3rd program after preclinical stage
- Financial terms remain undisclosed but incl. an upfront, milestones, royalties, Series A investment, & research funding from Pierre to RedRidge. R&D costs for co-development programs will be shared
Ref: PRNewsWire | Image: Pierre Fabre Laboratories & RedRidge Bio
Related News:- Pierre Fabre Laboratories Reports the EC’s Approval of Braftovi Plus Mektovi to Treat Advanced Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
